Short-term human safety data for ipamorelin, coming from a real clinical trial in surgical patients, showed an adverse event rate no higher than placebo. This reassuring finding, however, comes from a narrow, closely monitored population over a short period of time. Several specific side-effect questions that people commonly ask—water retention, hunger, cortisol, cancer risk—require looking at separate studies on the broader ghrelin receptor system that ipamorelin activates. The basic ipamorelin studies themselves did not directly measure all of these outcomes.
What are the side effects of Ipamorelin?
The most direct clinical safety data available for ipamorelin come from a randomised, placebo-controlled, phase 2, multicentre trial in patients recovering from bowel resection surgery. Ipamorelin was administered as an intravenous infusion twice daily for up to seven days. In this trial, the overall incidence of any treatment-related adverse event was 87.5% in the ipamorelin group, compared with 94.8% in the placebo group. This indicates that adverse events were not reported more frequently with ipamorelin than with placebo in this specific, hospitalised, closely monitored surgical population [1].
It is important to understand what this discovery does and does not say. It reflects a short-term, intravenous, medically supervised use case in individuals recovering from surgery. It does not represent long-term safety data, self-administered subcutaneous use or use in a healthy population seeking wellness or performance benefits. Nor did the study provide a detailed, itemised breakdown of every specific minor symptom experienced by the participants.
Besides this study, basic pharmacological investigations of ipamorelin have established something reassuring. It does not significantly increase cortisol, ACTH, prolactin, FSH, LH, or TSH, even at doses well exceeding those needed to trigger the release of growth hormone. This is a notable point of reassurance regarding several specific hormonal side effects, discussed in more detail below [2].
Does ipamorelin cause water retention, flushing or bloating?
No study identified in the peer-reviewed literature reviewed for this article specifically measured water retention, flushing, bloating, skin rash, headaches or burning at the injection site as outcomes in individuals using ipamorelin. These specific symptoms therefore remain unconfirmed by direct clinical data, rather than established or ruled out. Regarding flushing specifically, there is a genuine, scientifically plausible mechanism worth explaining. Ipamorelin works by activating the ghrelin receptor. Separate, peer-reviewed studies on ghrelin itself, the natural hormone that this receptor evolved to respond to, have documented that ghrelin acts as a vasodilator. It reduces vascular resistance through a direct action on vascular smooth muscle [3].
Because expanded blood vessels close to the skin surface are a general, well-established mechanism behind redness in medicine more broadly, this offers a plausible explanation for why some individuals report facial redness or flushing following the administration of ipamorelin. However, it is important to be precise. This links two separate research elements—the documented vasodilatory effect of ghrelin and ipamorelin’s known activation of the same receptor—rather than a study that directly measured redness following an injection of ipamorelin specifically.
Water retention and bloating are not addressed by any dedicated ipamorelin study identified here. The general physiology of growth hormone, discussed in connection with CJC-1295 elsewhere in this series, documents fluid retention as a recognised effect of elevated growth hormone activity. However, this has not been separately confirmed for ipamorelin via direct measurement.
Does ipamorelin cause hunger, weight gain or insulin resistance?
This is one of the more evidence-supported concerns about side effects specific to ipamorelin. It connects directly and logically to the receptor system that this compound activates. Ghrelin, the natural hormone whose receptor ipamorelin mimics, is extensively documented in endocrinological research as the body's primary „hunger hormone”. A comprehensive scientific review explained that ghrelin is the only known, peripherally produced hormone that increases appetite and the resulting food intake. It works by activating specific appetite-stimulating neurons in the arcuate nucleus of the brain [4].
Because ipamorelin activates the same receptor pathway, the appetite-increasing effect is mechanistically plausible. This expectation is directly supported by animal data. Studies analysing the growth hormone-independent effects of GH secretagogues showed that ipamorelin treatment in mice increased food intake and serum leptin levels, along with increased body weight and adipose tissue. This occurred via a mechanism that appeared to be independent of growth hormone itself [5].
This is a genuinely significant finding. It suggests that ipamorelin's activation of the ghrelin pathway associated with appetite may work against, rather than in favour of, the goal of weight management. This is a point worth taking seriously, given how differently this compound is often marketed.
Regarding insulin and blood sugar specifically, separate animal studies analysed the direct effect of ipamorelin on the pancreas. They showed that ipamorelina induced significant increases in insulin secretion from pancreatic tissue, in both normal and diabetic rats, via calcium channel and adrenergic receptor pathways [6]. This finding describes stimulated insulin release rather than a documented effect of insulin resistance. However, it is worth noting that these remain animal tissue studies, rather than a human clinical trial measuring blood sugar control or insulin sensitivity over time.
No human study identified in this article measured changes in blood pressure with ipamorelin. However, it is worth noting that the ghrelin-related vasodilation mechanism discussed above would theoretically be more consistent with lowered rather than elevated blood pressure. This point remains speculative without direct measurement.
Does ipamorelin cause cancer, cortisol or prolactin problems?
Regarding cortisol and prolactin specifically, ipamorelin has a genuine, well-documented calming effect. Its basic pharmacological profile directly tested and confirmed that it does not significantly raise either of these hormones, even at doses over 200 times higher than those needed for its growth hormone effect. This clearly distinguishes it from older-generation compounds, such as GHRP-2 and GHRP-6, which raised both [2]. This is one of the most frequently cited and best-supported safety features of ipamorelin.
Regarding cancer risk, no study identified within these reviews directly measured cancer incidence in individuals using ipamorelin. This question therefore cannot be answered with direct human evidence.
What can be said, in line with the broader discussion of this topic for CJC-1295 elsewhere in this series, is this. The downstream effect of ipamorelin on IGF-1, which is assumed rather than directly confirmed by measurement in humans as discussed in the earlier article, would carry the same general, theoretical concern that applies to the growth hormone-IGF-1 axis more broadly. IGF-1 is recognised in mainstream endocrinology as having cell growth-stimulating effects. A 2026 review covering performance-enhancing peptides on this axis, including ipamorelin, described such concerns as „biologically plausible, yet unproven”. This is an appropriately cautious characterisation that applies here too [7].
Regarding anxiety, insomnia, and fertility, no dedicated study of ipamorelin has addressed these specific outcomes in humans. The ghrelin receptor system has been documented in broader studies as playing a role in brain pathways related to stress and anxiety [8]. However, this describes the known biology of the general receptor system rather than a discovery specific to ipamorelin itself.
Limitations of current evidence
The short-term safety of ipamorelin in a monitored surgical population is documented by real-world clinical trial data [1]. Its lack of a significant effect on cortisol and prolactin is well established by its basic pharmacology [2].
However, several specific side effects that people commonly ask about, including water retention, flushing, bloating, skin reactions, blood pressure, anxiety, insomnia, and fertility, have not been directly measured in a dedicated ipamorelin study. Conclusions about these are based on mechanistic reasoning combined with the broader ghrelin receptor system rather than direct clinical findings.
The appetite-stimulating and fat-gaining effects found in animal studies represent a real and concrete concern that contradicts the common marketing claims about this compound [5].
Disclaimer
Ipamorelin is not approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory body for any human use, and no regulatory body has established an official, comprehensive safety profile for this compound outside the narrow context of surgical recovery in which it was most directly studied. It is not manufactured or sold under the quality and safety oversight that applies to approved pharmaceuticals. Safety information in this article is derived from a limited number of clinical and animal studies and recent scientific reviews, and does not establish a comprehensive human safety profile for general or long-term use. This article is provided for general educational and informational purposes only, reflects the state of the published scientific literature at the time of writing, and does not constitute medical advice. Anyone experiencing any side effect while using this or any peptide compound should immediately consult a licensed healthcare professional.
References
[1] Beck, D. E., Sweeney, W. B., McCarter, M. D., & the Ipamorelin 201 Study Group. (2014). A prospective, randomised, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in patients who have undergone bowel resection. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[2] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
[3] DeBoer, M. D. (2012). The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: Efficacy and mechanism. Current Pharmaceutical Design, 18(31), 4779–4799. https://doi.org/10.2174/138161212803216951
[4] Howick, K., Griffin, B. T., Cryan, J. F., & Schellekens, H. (2017). From belly to brain: Targeting the ghrelin receptor in appetite and food intake regulation. International Journal of Molecular Sciences, 18(2), Article 273. https://doi.org/10.3390/ijms18020273
[5] Lall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., & Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and Biophysical Research Communications, 280(1), 132–138. https://doi.org/10.1006/bbrc.2000.4065
[6] Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters, 25(6), 403–406.
[7] Dominikowski, A., Rękoś, Z., Olejarz, M., Szczepanek-Parulska, E., Domin, R., & Ruchała, M. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: Bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 17, Article 1822475. https://doi.org/10.3389/fendo.2026.1822475
[8] Howick, K., Griffin, B. T., Cryan, J. F., & Schellekens, H. (2017). From belly to brain: Targeting the ghrelin receptor in appetite and food intake regulation. International Journal of Molecular Sciences, 18(2), Article 273. https://doi.org/10.3390/ijms18020273